UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Steady and Transient CFD Approach for Port Optimization

SAE International journal of materials and manufacturing, 2009-01, Vol.1 (1), p.754-762, Article 2008-01-1430

2009

Volltextzugriff (PDF)

Cardiac Dysrhythmias After Loperamide Abuse — New York, 2008–2016

MMWR. Morbidity and mortality weekly report, 2016, Vol.65 (45), p.1276-1277

2016

Volltextzugriff (PDF)

Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse - New York, 2008-2016

MMWR. Morbidity and mortality weekly report, 2016-11, Vol.65 (45), p.1276-1277

2016

Volltextzugriff (PDF)

China's Tariff Autonomy, Fact or Myth

Far Eastern survey, 1936-06, Vol.5 (12), p.115-122

1936

Volltextzugriff (PDF)

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021

MMWR. Morbidity and mortality weekly report, 2021-05, Vol.70 (18), p.680-684

2021

Volltextzugriff (PDF)

COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021

MMWR. Morbidity and mortality weekly report, 2021-08, Vol.70 (31), p.1053-1058

2021

Volltextzugriff (PDF)

COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021

MMWR. Morbidity and mortality weekly report, 2021-12, Vol.70 (5152), p.1755-1760

2021

Volltextzugriff (PDF)

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021

MMWR. Morbidity and mortality weekly report, 2022-01, Vol.71 (3), p.90-95

2022

Volltextzugriff (PDF)

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021

MMWR. Morbidity and mortality weekly report, 2021-08, Vol.70 (32), p.1094-1099

2021

Volltextzugriff (PDF)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022

MMWR. Morbidity and mortality weekly report, 2022-03, Vol.71 (9), p.347-351

2022

Volltextzugriff (PDF)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022

MMWR. Morbidity and mortality weekly report, 2022-02, Vol.71 (7), p.249-254

2022

Volltextzugriff (PDF)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022

MMWR. Morbidity and mortality weekly report, 2022-11, Vol.71 (44), p.1401-1406

2022

Volltextzugriff (PDF)

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022

MMWR. Morbidity and mortality weekly report, 2022-07, Vol.71 (30), p.971-976

2022

Volltextzugriff (PDF)

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022

MMWR. Morbidity and mortality weekly report, 2022-09, Vol.71 (35), p.1115-1120

2022

Volltextzugriff (PDF)

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021

MMWR. Morbidity and mortality weekly report, 2021-05, Vol.70 (18), p.685-688

2021

Volltextzugriff (PDF)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023

MMWR. Morbidity and mortality weekly report, 2023-01, Vol.72 (2), p.39-43

2023

Volltextzugriff (PDF)

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022

MMWR. Morbidity and mortality weekly report, 2022-08, Vol.71 (33), p.1047-1051

2022

Volltextzugriff (PDF)

Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine - United States, May 3, 2023-April 14, 2024

MMWR. Morbidity and mortality weekly report, 2024-05, Vol.73 (21), p.489-494

2024

Volltextzugriff (PDF)

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022

MMWR. Morbidity and mortality weekly report, 2022-07, Vol.71 (28), p.899-903

2022

Volltextzugriff (PDF)

Acanthamoeba Keratitis — Multiple States, 2005–2007

MMWR. Morbidity and mortality weekly report, 2007-06, Vol.56 (21), p.532-534

2007

Volltextzugriff (PDF)

Briefings

American scientist, 2014-07, Vol.102 (4), p.249

2014

Volltextzugriff (PDF)

Use of Quarantine to Prevent Transmission of Severe Acute Respiratory Syndrome — Taiwan, 2003

MMWR. Morbidity and mortality weekly report, 2003-07, Vol.52 (29), p.680-683

2003

Volltextzugriff (PDF)

Nosocomial Transmission of Mycobacterium tuberculosis Found Through Screening for Severe Acute Respiratory Syndrome — Taipei, Taiwan, 2003

MMWR. Morbidity and mortality weekly report, 2004-04, Vol.53 (15), p.321-322

2004

Volltextzugriff (PDF)

Development of a Coupled Leaf and Canopy Model for the Simulation of Plant-Atmosphere Interaction

Journal of applied meteorology (1988), 1996-05, Vol.35 (5), p.733-748

1996

Volltextzugriff (PDF)

1 – 25 von 307

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

KollektionJSTOR

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(300)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Public Health
(19)
Science & Technology
(19)
Bibliografia
(16)
Full Report
(16)
Vaccines
(16)
Coronaviruses
(15)
Covid-19
(15)
Covid-19 Vaccines
(15)
Humans
(15)
Life Sciences & Biomedicine
(15)
Immunization
(14)
Public, Environmental & Occupational Health
(14)
Myocarditis
(13)
Pharmaceutical Industry
(13)
Surveillance
(13)
Safety And Security Measures
(12)
Vaccination
(12)
Mrna
(10)
Female
(9)
Hospitalization
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Steady and Transient CFD Approach for Port Optimization

Cardiac Dysrhythmias After Loperamide Abuse — New York, 2008–2016

Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse - New York, 2008-2016

China's Tariff Autonomy, Fact or Myth

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021

COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021

COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022

Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023

The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022

Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine - United States, May 3, 2023-April 14, 2024

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022

Acanthamoeba Keratitis — Multiple States, 2005–2007

Briefings

Use of Quarantine to Prevent Transmission of Severe Acute Respiratory Syndrome — Taiwan, 2003

Nosocomial Transmission of Mycobacterium tuberculosis Found Through Screening for Severe Acute Respiratory Syndrome — Taipei, Taiwan, 2003

Development of a Coupled Leaf and Canopy Model for the Simulation of Plant-Atmosphere Interaction

Aktive Filter

Suchergebnisse filtern